Samuel Richard Schnittman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 3 | 2024 | 820 | 1.190 |
Why?
|
| Hepatitis B Vaccines | 1 | 2021 | 194 | 0.710 |
Why?
|
| Aortic Valve | 3 | 2018 | 1920 | 0.680 |
Why?
|
| HIV Infections | 7 | 2024 | 16715 | 0.620 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2017 | 1537 | 0.570 |
Why?
|
| Labor, Induced | 1 | 2017 | 146 | 0.550 |
Why?
|
| Bioprosthesis | 2 | 2017 | 597 | 0.550 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 999 | 0.530 |
Why?
|
| Immune System | 1 | 2021 | 807 | 0.530 |
Why?
|
| Hepatitis B | 1 | 2021 | 693 | 0.520 |
Why?
|
| Pulmonary Valve | 1 | 2017 | 437 | 0.450 |
Why?
|
| Heart Valve Prosthesis | 3 | 2018 | 1489 | 0.430 |
Why?
|
| Mitral Valve | 2 | 2017 | 1491 | 0.410 |
Why?
|
| Choice Behavior | 1 | 2017 | 802 | 0.400 |
Why?
|
| Postoperative Care | 1 | 2016 | 1485 | 0.350 |
Why?
|
| Cytomegalovirus | 3 | 2024 | 733 | 0.340 |
Why?
|
| Aortic Valve Stenosis | 2 | 2018 | 1955 | 0.320 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 4255 | 0.260 |
Why?
|
| Hemorrhage | 1 | 2017 | 3458 | 0.260 |
Why?
|
| California | 2 | 2017 | 1402 | 0.230 |
Why?
|
| HIV-1 | 1 | 2021 | 6939 | 0.220 |
Why?
|
| Heart Transplantation | 1 | 2016 | 3113 | 0.220 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 6485 | 0.220 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2021 | 90 | 0.200 |
Why?
|
| Prosthesis Design | 2 | 2017 | 2103 | 0.190 |
Why?
|
| Kynurenine | 1 | 2021 | 139 | 0.190 |
Why?
|
| Chemokine CXCL10 | 1 | 2021 | 305 | 0.180 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2021 | 294 | 0.180 |
Why?
|
| Tryptophan | 1 | 2021 | 478 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 357 | 0.170 |
Why?
|
| HIV | 2 | 2023 | 1604 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 15142 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2018 | 15281 | 0.140 |
Why?
|
| Rheumatic Heart Disease | 1 | 2017 | 177 | 0.130 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2017 | 143 | 0.130 |
Why?
|
| New York City | 1 | 2017 | 705 | 0.130 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3175 | 0.130 |
Why?
|
| New York | 1 | 2017 | 885 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 2560 | 0.120 |
Why?
|
| Stroke | 1 | 2017 | 9975 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 4561 | 0.120 |
Why?
|
| Patient Care Management | 1 | 2017 | 306 | 0.120 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 409 | 0.120 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 579 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 1714 | 0.110 |
Why?
|
| Viral Load | 1 | 2021 | 3300 | 0.100 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 1203 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 2865 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3208 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2022 | 1518 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2021 | 4026 | 0.090 |
Why?
|
| Age Factors | 2 | 2017 | 18355 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2023 | 4386 | 0.090 |
Why?
|
| Female | 9 | 2024 | 380020 | 0.090 |
Why?
|
| Male | 8 | 2024 | 349776 | 0.080 |
Why?
|
| Humans | 12 | 2024 | 743811 | 0.080 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 1365 | 0.080 |
Why?
|
| Reoperation | 1 | 2017 | 4200 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2017 | 1470 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2017 | 2922 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2017 | 4197 | 0.070 |
Why?
|
| Middle Aged | 5 | 2023 | 213241 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2022 | 3445 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2016 | 5078 | 0.070 |
Why?
|
| Adolescent | 3 | 2021 | 85729 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2021 | 77410 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39001 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 10251 | 0.060 |
Why?
|
| Adult | 4 | 2021 | 213889 | 0.060 |
Why?
|
| Young Adult | 2 | 2021 | 56392 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2017 | 7729 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2017 | 63042 | 0.050 |
Why?
|
| Incidence | 1 | 2017 | 20948 | 0.040 |
Why?
|
| Muscles | 1 | 2024 | 1613 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 40545 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2017 | 23327 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 40038 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 29140 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 35122 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 40964 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 163178 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 72252 | 0.020 |
Why?
|
| Child | 1 | 2016 | 77637 | 0.020 |
Why?
|
| Macrophages | 1 | 2022 | 5651 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5096 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57744 | 0.010 |
Why?
|